Editorial

Von Hippel-Lindau disease and pregnancy

ANDREW SHAH, M.D., AND E. ANTONIO CHIOCCA, M.D., PH.D.

Department of Neurological Surgery, Wexner Medical Center at The Ohio State University, Columbus, Ohio

Hemangioblastomas associated with von Hippel-Lindau (VHL) disease are thought to exhibit accelerated tumor growth, progression, and cyst formation in pregnancy, although the mechanism is poorly understood. Pregnancy is known to aggravate brain tumors by 3 mechanisms: acceleration of growth, increased edema, and immunotolerance to foreign antigens. Von Hippel-Lindau disease is an autosomal dominant neurocutaneous dysplastic condition found on chromosome 3p25-26. The VHL gene is involved in expression of VEGF, making it important for normal extraembryonic vasculogenesis. Hemangioblastomas are composed of endothelium and stromal cell components. Pregnancy results in a high estrogen state, which stimulates endothelial proliferation and has been associated with growth of hemangiomas despite the lack of estrogen receptors in the lesions. Grimbert et al. performed a retrospective study of 30 women patients with VHL disease. When these patients became pregnant, several case reports have shown that symptomatic lesions can be safely resected in pregnancy. Finally, symptomatology from cerebellar hemangioblastomas is an indication for surgery in VHL disease and occurs at a mean age of 33 years.

In their article, Ye et al. address the effect of pregnancy on hemangioblastomas in the setting of VHL disease. They performed a prospective study with serial clinical and imaging in patients with VHL disease who became pregnant and compared findings during pregnancy with findings obtained during the time that these women were not pregnant. They also compared these findings with those of a separate cohort of patients with VHL disease who did not become pregnant during the study period. Thirty-six consecutive female patients between 16 and 35 years of age were included, with a total of 177 hemangioblastomas. The mean follow-up period ± SD was 7.5 ± 2.3 years. Serial evaluations at 6- and 12-month intervals were performed before and after pregnancy. Craniospinal MRI was used for identification and quantification of the number of hemangioblastomas, cysts, and peritumoral edema. Tumor volumes were calculated using a modified ellipsoid formula at each visit. In the pregnancy cohort, there were 20 cerebellar, 2 brainstem, and 9 spinal cord hemangioblastomas. In the no-pregnancy cohort, there were 27 patients with 145 hemangioblastomas. In the pregnancy cohort, the mean rate of new tumor and peritumoral cyst development during the time when the women were pregnant (0.4 ± 0.4 tumors/year) did not differ significantly from the rate during the time when they were not pregnant (0.3 ± 0.4 tumors/year). The rate was also similar to that of the no-pregnancy cohort (0.3 ± 0.5 tumors/year). The annualized growth rate during pregnancy was 29.8% ± 42.7%, and the rate of growth for the same tumors during the time that the women were not pregnant was 41.4% ± 51.4%, which was not different from the growth rates in the no-pregnancy cohort. The rate of peritumoral cyst development was also similar in the pregnancy and no-pregnancy cohorts, but was higher during the nonpregnant periods in the pregnancy cohort. The need for surgery and the average age at surgery did not differ significantly between the pregnancy cohort (surgery required for 28% of hemangioblastomas, mean patient age at surgery 30.2 years) and no-pregnancy cohort (19%, 32.3 years).

This study provides new insight into the effect of pregnancy on hemangioblastomas but does have limitations. First, the sample size of the pregnancy cohort is small and may not be powered enough to detect small differences in growth rates. Also there is some inherent bias as patients self-select to become pregnant. Further, baseline differences in tumor characteristics (size, location, neurological impairment) may have limited those in the no-pregnancy cohort from becoming or attempting to become pregnant. The tumor volume was estimated utilizing an ellipsoid formula, but it is unclear if the measurements were verified to confirm accuracy. Furthermore, it is unclear if the measurements were performed in a blinded fashion by an independent reviewer. Curiously, peritumoral cyst growth rates were higher in the nonpregnant period in the pregnancy cohort compared to both the rate during pregnancy and the rate in the no-pregnancy cohort. This indicates a need for further investigation to determine what changes occur in the nonpregnant period that lead to cyst progression.
Nevertheless, Ye et al. should be commended for performing the first prospective study that directly addresses the effect of pregnancy on rates of tumor growth and progression as well as development of new tumors and peritumoral cysts by a direct comparison of radiological data obtained in a group of VHL disease patients during pregnancy and during times when these same individuals were not pregnant, as well as similar data obtained in patients who did not become pregnant during the study period. The internal control of the comparison of the pregnant and nonpregnant periods in the pregnancy cohort further emphasized the safety of pregnancy in these individuals. The findings directly challenge the notions that cyst progression and hemangioblastoma growth are accelerated during pregnancy. This study will provide guidance to both obstetricians and neurosurgeons when it comes to educating and managing patients with VHL disease who are or may become pregnant. (http://thejns.org/doi/abs/10.3171/2012.4.JNS12539)

Disclosure

The authors report no conflict of interest.

References


Response

DONALD Y. YE, B.A., KAMRAN D. BAKHTIAN, M.S., ASHOK R. ASTHAGIRI, M.D., AND RUSSELL R. LONSER, M.D.

Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

We appreciate Dr. Shaw’s and Dr. Chiocca’s insightful comments regarding our study. Given the paucity of clinical evidence describing the effect of pregnancy on the development and progression of hemangioblastomas and associated cysts in patients with VHL disease, we sought to quantify the impact that pregnancy has on CNS hemangioblastoma progression and symptom development in this neoplastic disorder. Specifically, we prospectively analyzed and compared the development and progression of CNS hemangioblastomas and associated cysts (177 tumors, 28 cysts) in reproductive-age female patients with VHL disease who became pregnant (32 tumors, 5 cysts) versus the same growth and development in a cohort of reproductive-aged female VHL disease patients who did not become pregnant (145 tumors, 23 cysts). Further, we analyzed for potential individual biological differences by comparing hemangioblastoma and cyst development and progression within the pregnancy cohort during the periods when the women were pregnant and the periods when they were not.

Whereas prior case reports suggested that pregnancy could alter development and progression of CNS hemangioblastomas and/or associated cysts,1–9 this prospective long-term analysis (mean follow-up 7.5 ± 2.3 years) of serial clinical and MRI evaluations demonstrated no significant difference between the pregnancy and no-pregnancy cohorts with respect to the development or progression of hemangioblastomas and associated cysts. Moreover, in the pregnancy cohort, there was no significant difference in the development or progression of hemangioblastomas and associated cysts during the time the women were pregnant compared with the time when they were not pregnant. Specifically, hemangioblastomas demonstrated similar growth during pregnancy (30% growth per year) compared to nonpregnant periods (41%) and to the tumors in the cohort of women who did not become pregnant (34%). Peritumoral cysts grew at similar rates in the no-pregnancy cohort (48%) and during pregnancy in the pregnancy cohort (51% per year). Finally, cyst growth was higher during nonpregnant periods in the pregnant cohort, which underscored the fact that pregnancy does not accelerate cyst progression.

Previous reports that suggested pregnancy enhances hemangioblastoma and/or cyst development or progres-
sion were limited by several factors, which may explain the differences reflected in the current study. Prior reports lacked prospective longitudinal imaging before and after symptom development. They were also inconclusive due to a paucity of patients (frequently case reports) and tumors. The anecdotal observation of symptomatic hemangioblastomas associated with pregnancy led many to assume a causal relationship. A more likely explanation for the finding of symptomatic hemangioblastomas in pregnant patients is that pregnancies often occur during the time when symptoms associated with hemangioblastomas typically arise (20–40 years of age). The mean age for symptom development of CNS hemangioblastomas in VHL disease patients described by Wanebo and colleagues10 (33 years) is similar to the mean age of pregnancy (30 years) and within the range of pregnancy ages (20–35 years) seen in this study.

Overall, the objective of the study was to detect pregnancy-induced differences in hemangioblastoma and associated cyst development and progression to better guide management and deepen understanding of tumor biology. Although the numbers of tumors and patients (177 hemangioblastomas in 36 patients) in our study could limit detection of small effects, this cohort of VHL disease patients is the largest single prospective cohort under investigation, and the large total number of tumors and cysts provides a sufficient sample size to detect medium-sized and large effects in both a paired and an unpaired analysis. None of these effects was evident in this study. While self-selection could have influenced patient decisions to become pregnant, there were no significant differences in CNS hemangioblastoma disease burden between patients in the pregnancy and no-pregnancy cohorts. Finally, with respect to the accuracy of tumor and cyst measurements, the measurements were performed by 2 independent blinded investigators who recorded tumor size before identification of the pregnancy and no-pregnancy cohorts.

While further investigation is certainly required to understand the biology of hemangioblastoma development and growth, as well as the processes that lead to cyst formation and expansion, better understanding of the clinical progression of VHL disease during pregnancy can help alleviate many of the concerns that VHL disease patients and physicians managing their disease may have about the safety of pregnancy and its influence on CNS hemangioblastomas and their accompanying cysts.

References


Please include this information when citing this paper: published online August 31, 2012; DOI: 10.3171/2012.4.JNS12539.